What is the recommended treatment for lichen planus?

Treatment of Lichen Planus

High-potency topical corticosteroids, specifically clobetasol propionate 0.05%, are the first-line treatment for lichen planus across all variants, with the strongest evidence supporting their use in cutaneous and oral disease. 1, 2, 3, 4

Treatment Algorithm by Disease Location

Cutaneous Lichen Planus

First-Line Therapy:

• Clobetasol propionate 0.05% ointment applied once daily is the gold standard 1
• Alternative high-potency options include fluocinonide 0.05% cream or ointment 1
• For scalp involvement, use solution formulations; for other areas, use cream/lotion/ointment 1
• Evidence quality is high for topical corticosteroids, making them superior to other options 4

Second-Line Therapy (if inadequate response after 4-6 weeks):

• Tacrolimus 0.1% ointment for steroid-resistant cases 1
• Narrow-band UVB phototherapy if available, particularly effective for widespread disease 1, 5
• Oral antihistamines for pruritus control 1

Third-Line Therapy (moderate to severe disease):

• Oral prednisone (dose and duration should be tapered over 3 weeks once symptoms improve to Grade 1) 1
• Acitretin has demonstrated increased overall response rates versus placebo 5
• Methotrexate shows efficacy with comparable complete response rates to oral betamethasone 5

Oral Lichen Planus

First-Line Therapy:

• Topical corticosteroids remain the most cost-effective and efficacious option: fluocinonide > dexamethasone > clobetasol > triamcinolone 2, 3
• Use gel formulations for mucosal disease 1
• Topical corticosteroids achieve clinical improvement with RR 1.35-1.37 2

Second-Line Therapy:

• Topical calcineurin inhibitors (tacrolimus > pimecrolimus > cyclosporine) are significantly efficacious (RR 1.38) but have higher adverse effect rates (RR 3.25) 2, 3
• Aloe vera shows promise with RR 1.53 for clinical symptom improvement 2

Third-Line Therapy:

• Photodynamic therapy demonstrates statistically significant improvement in clinical scores (MD = -5.91) 2
• Intralesional triamcinolone for localized erosive lesions 3
• Low-level laser therapy shows efficacy in multiple trials 3

Emerging and Novel Therapies

For Refractory Disease:

• JAK inhibitors (particularly tofacitinib) represent a dramatic advancement in treatment landscape 6
• Apremilast (phosphodiesterase-4 inhibitor) shows promise as a pathogenesis-driven treatment 6
• Biologics targeting IL-23/IL-17 pathway are under investigation 6

Treatment Duration and Monitoring

• Continue high-potency topical corticosteroids until hyperkeratosis, ecchymoses, fissuring, and erosions resolve (typically 4-12 weeks) 1
• Taper systemic corticosteroids over 3 weeks once symptoms improve to Grade 1 1
• Long-term maintenance with topical corticosteroids as needed for flares is safe and effective 4

Critical Caveats

Safety Considerations:

• Topical calcineurin inhibitors, while effective, carry significantly higher adverse effect rates compared to topical corticosteroids 2
• Erosive/ulcerative oral forms pose the greatest therapeutic challenge and often require combination therapy 7
• Monitor for malignant transformation, particularly in hypertrophic cutaneous and mucosal variants 6

Treatment Resistance:

• If no response after 6 weeks of high-potency topical corticosteroids, escalate to systemic therapy 1
• Consider combination approaches (topical + phototherapy or topical + systemic) for widespread or refractory disease 5
• Psychological evaluation and support should be integrated given frequent quality of life impairment 6

Evidence Limitations:

• Most alternative therapies (hydroxychloroquine, sulfasalazine, griseofulvin) have low to very low quality evidence 4, 5
• No FDA/EMA-approved drugs specifically for lichen planus exist, making most treatments off-label 7
• Large-scale randomized controlled trials comparing head-to-head interventions are still needed 3, 4